New Horizons in Non-Hodgkin’s Lymphoma (NHL): Endpoints and Outcomes in Follicular Lymphoma

A recording of the 1.5-hour live webinar held in April 2018 with experts from Australia, the UK and the US, presenting and weighing in on the issues surrounding clinical trial endpoints and their clinical application.

TARGET AUDIENCE

The primary audience of this activity are haematologists and oncologists, but the entire clinical team (e.g. nurses/nurse counselors, radiotherapists, diagnostic radiologist) would be indirectly targeted by encouraging interdisciplinary collaboration and training in their own practices.

LEARNING OUTCOME STATEMENTS

At the conclusion of this activity:

KNOWLEDGE: Using pre- and post-activity tests, participants will self-report whether their knowledge increased as a result of attending this webinar

COMPETENCE/SKILL: Based on their participation in the Q&A session, responses to the pre- and post-activity tests, and self-report of competence and intention to change, participants should be able to demonstrate their improved competence and skill as a result of attending this webinar

PERFORMANCE: Participants will self-report changes in their practice as a result of attending this webinar

EDUCATIONAL OBJECTIVES

Upon completion of this activity, participants will be better able to:

  1. List the advantages and limitations of endpoints used in clinical trials, and be able to explain the reasons why it may be appropriate to consider endpoints other than overall survival (OS) when assessing data from clinical trials on NHL
  2. Interpret common statistical concepts relating to diagnosis and treatment and infer how statistical data apply in their clinical practice
  3. Appraise the information to be gained from the results of particular clinical trials based on the endpoints used
  4. Communicate expected outcomes of therapy based on results of clinical studies

FACULTY

Prof. John F. Seymour
Director, Peter MacCallum Cancer Centre
Victorian Comprehensive Cancer Centre
Faculty of Medicine
University of Melbourne
Melbourne, Victoria, Australia

Prof. Tim Illidge
Head of Division of Cancer Sciences
University of Manchester
Manchester, UK

Prof. James O. Armitage
Joe Shapiro Professor of Medicine
University of Nebraska Medical Center
Omaha, Nebraska, USA

Disclosure of Conflicts of Interest

It is the policy of the Elsevier Office of Continuing Medical Education (EOCME) and Elsevier that all faculty, instructors, and planners disclose any real or apparent conflicts of interest relating to the topics of this educational activity.

The faculty reported the following financial relationships or relationships to products or devices they or their life partner have with commercial interests related to the content of this CME activity:

FacultyRelationship Identified With:
Prof. John F. Seymour

Consultant/Advisor: Abbvie Inc.; Celgene Corporation; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; F. Hoffman–La Roche Ltd.; Sunesis Pharmaceuticals, Inc.; Takeda Pharmaceutical Company

Grant/Research Support: Abbvie Inc.; Celgene Corporation; Janssen Pharmaceuticals, Inc.; F. Hoffman–La Roche Ltd.

Speakers’ bureau: Abbvie Inc.; Celgene Corporation; F. Hoffman–La Roche Ltd.

Prof. Tim Illidge

Consultant/Advisor: Takeda Pharmaceutical Company Limited

Grant/Research Support: F. Hoffman–La Roche Ltd.; Merck & Co., Inc.

Speakers’ Bureau: F. Hoffman–La Roche Ltd.; Merck & Co., Inc.; Takeda Pharmaceutical Company Limited

Prof. James O. Armitage

Board of Directors: TESARO, Inc.

Consultant/Advisor: Ascentage Pharma; Conatus IDMC; Samus Therapeutics, Inc.

Non-faculty: Tina Garcia, Lisa Sullivan; Sandy Breslow; Alison Kemp; Marilu Kelly, MSN, RN, CNE, and Bernard M. Abrams, MD hereby state that neither they nor their spouse/life partner have had any financial relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Financial Support

This activity has been supported by an independent educational grant from F. Hoffman–La Roche Ltd.

PROVIDER INFORMATION

Jointly provided by the Elsevier Office of Continuing Medical Education, Elsevier, and In Vivo Academy Limited.

CME CREDIT (PHYSICIANS)

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Elsevier Office of Continuing Medical Education (EOCME) and In Vivo Academy. The Elsevier Office of Continuing Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

The Elsevier Office of Continuing Medical Education designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CNE CREDIT (NURSES)

This continuing nursing education activity, provided by Elsevier, awards 1.5 contact hours for nurses. Elsevier is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Elsevier is provider approved by the Florida Board of Nursing, Provider #50-4681. Provider approved by the California Board of Registered Nursing, Provider #CEP 3257, for 1.5 contact hours.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of EOCME, Elsevier, and In Vivo Academy Limited.

CME/CNE INQUIRIES/SPECIAL NEEDS

For all CME inquiries or special needs, please contact elsevierCME@elsevier.com.

For all CNE inquiries or special needs, please contact p.harvey@elsevier.com.


Disclosure of Unlabeled Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration (FDA). The EOCME, Elsevier, In Vivo Academy Limited, and F. Hoffman–La Roche Ltd do not recommend the use of any agent outside the labeled indications.

Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Course summary
Available credit: 
  • 1.50 AMA PRA Category 1 Credit(s)™
  • 1.50 Nursing Contact Hours
  • 1.50 Non-physician
Course opens: 
08/07/2018
Course expires: 
08/06/2019
Rating: 
0

Available Credit

  • 1.50 AMA PRA Category 1 Credit(s)™
  • 1.50 Nursing Contact Hours
  • 1.50 Non-physician

Accreditation Period

Course opens: 
08/07/2018
Course expires: 
08/06/2019
Please login or register to take this course.